Sunday, 4 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

NEW SOURCES ENERGY Stock 10% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with NEW SOURCES ENERGY (NSE.AS) jumping 10% to €0.04 on Wednesday, after two successive sessions in a row of losses. AEX-Index jumped 0.15% to €793.69, following the last session's upward trend on what was a somewhat up trend exchanging session today.

NEW SOURCES ENERGY's last close was €0.04, 38.46% below its 52-week high of €0.07.

About NEW SOURCES ENERGY

New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.

Yearly Top and Bottom Value

NEW SOURCES ENERGY's stock is valued at €0.04 at 21:31 EST, way below its 52-week high of €0.07 and way higher than its 52-week low of €0.01.

More news about NEW SOURCES ENERGY (NSE.AS).

Categories

stockMarket

Tags

Market-Close NowStock PriceClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpNSE.ASNEW SOURCES ENERGYStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com